BCAL Diagnostics (ASX:BDX) Change In Receivables : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Change In Receivables?

BCAL Diagnostics's change in receivables for the quarter that ended in Dec. 2023 was A$0.00 Mil. It means BCAL Diagnostics's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

BCAL Diagnostics's change in receivables for the fiscal year that ended in Jun. 2023 was A$0.00 Mil. It means BCAL Diagnostics's Accounts Receivable stayed the same from Jun. 2022 to Jun. 2023 .

BCAL Diagnostics's Accounts Receivable for the quarter that ended in Dec. 2023 was A$0.01 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BCAL Diagnostics's liquidation value for the six months ended in Dec. 2023 was A$2.67 Mil.

BCAL Diagnostics Change In Receivables Historical Data

The historical data trend for BCAL Diagnostics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Change In Receivables Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Change In Receivables

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-

BCAL Diagnostics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

BCAL Diagnostics (ASX:BDX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BCAL Diagnostics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.007	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, BCAL Diagnostics's accounts receivable are only considered to be worth 75% of book value:

BCAL Diagnostics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5.017	-	2.355	+	0.75 * 0.007	+	0.5 * 0
=	2.67

BCAL Diagnostics Change In Receivables Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.